Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

被引：12
|
作者：
Russano, Marco [1 ]
La Cava, Giulia [1 ]
Cortellini, Alessio [1 ]
Citarella, Fabrizio [1 ]
Galletti, Alessandro [2 ]
Di Fazio, Giuseppina Rita [1 ]
Santo, Valentina [1 ]
Brunetti, Leonardo [1 ]
Vendittelli, Alessia [1 ]
Fioroni, Iacopo [1 ]
Pantano, Francesco [1 ]
Tonini, Giuseppe [1 ]
Vincenzi, Bruno [1 ]
机构：
[1] Campus Biomed Univ Rome, Dept Med Oncol, Via Alvaro Portillo 21, I-00128 Rome, Italy
[2] San Camillo Forlanini Hosp, Div Med Oncol, I-00152 Rome, Italy
来源：
CURRENT ONCOLOGY | 2023年 / 30卷 / 02期
关键词：
immunotherapy; non-small cell lung cancer; immune checkpoint inhibitors; PD-1; PD-L1; antibodies; combination strategies; biomarkers; tissue biomarkers; liquid biopsy; IMMUNE CHECKPOINT INHIBITORS; PD-L1; EXPRESSION; NSCLC PATIENTS; OPEN-LABEL; CHEMOTHERAPY CHEMO; 1ST-LINE NIVOLUMAB; ADVERSE EVENTS; CHECKMATE; 9LA; PATIENTS PTS; PHASE-III;
D O I：
10.3390/curroncol30020181
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. However, only a few patients have long-term benefits, and most of them do not respond or develop progressive disease during treatment. Thus, the identification of reliable predictive and prognostic biomarkers remains crucial for patient selection and guiding therapeutic choices. In this review, we provide an overview of the current strategies, highlighting the main clinical challenges and novel potential biomarkers.
引用
收藏
页码：2366 / 2387
页数：22
相关论文
共 50 条
  • [21] Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
    Duchemann, Boris
    Remon, Jordi
    Naigeon, Marie
    Cassard, Lydie
    Jouniaux, Jean Mehdi
    Boselli, Lisa
    Grivel, Jonathan
    Auclin, Edouard
    Desnoyer, Aude
    Besse, Benjamin
    Chaput, Nathalie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2937 - 2954
  • [22] Immunotherapy for Non-Small Cell Lung Cancer
    Yoon, Sung Ho
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2014, 77 (03) : 111 - 115
  • [23] Immunotherapy for non-small cell lung cancer
    Vafadar, Sam
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2019, 32 (09): : 37 - 42
  • [24] Immunotherapy in non-small cell lung cancer
    Peters, Geoffrey
    John, Thomas
    CANCER FORUM, 2018, 42 (01) : 24 - 28
  • [25] Immunotherapy for non-small cell lung cancer
    Kagamu, Hiroshi
    RESPIRATORY INVESTIGATION, 2024, 62 (02) : 307 - 312
  • [26] Immunotherapy in non-small cell lung cancer: current status, advances and challenges
    Tartarone, Alfredo
    Lerose, Rosa
    Tartarone, Marina
    MINERVA RESPIRATORY MEDICINE, 2024, 63 (03): : 110 - 120
  • [27] Immunotherapy for metastatic non-small cell lung cancer: Is it really a no-brainer?
    Young, Lauren K.
    Halmos, Balazs
    CANCER, 2024, 130 (15) : 2577 - 2581
  • [28] Immunotherapy in metastatic non-small cell lung cancer: EPSILoN as a prognostic score
    Valente, M. C. Alves
    Serino, M.
    Freitas, C.
    Martins, M.
    Ferreira, P.
    Cardoso, C.
    Sousa, C.
    Santos, V.
    Araujo, D.
    Novais-Bastos, H.
    Magalhaes, A.
    Queiroga, H.
    Fernandes, G.
    Hespanhol, V.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [29] Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
    Xiang, Yan
    Zhang, Shiyu
    Fang, Xiaoxu
    Jiang, Yingying
    Fang, Tingwen
    Liu, Jinwen
    Lu, Kaihua
    CURRENT ONCOLOGY, 2022, 29 (10) : 7816 - 7831
  • [30] Therapeutic options in older patients with metastatic non-small cell lung cancer
    Quoix, Elisabeth
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2012, 4 (05) : 247 - 254
12345